Blocking pro-invasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NASs). This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I.
Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma. The assay is now ...
The preventive effects of early short-course corticosteroids on immune-related adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors. Precision medicine-based ...
Agilent Technologies A has bolstered presence in the clinical and diagnostic testing market of Europe by expanding the use of PD-L1 IHC 22C3 pharmDx assay in patients suffering from esophageal cancer ...
U.S. Food and Drug Administration (FDA) has now approved a pharmDx assay called ‘Dako PD-L1 IHC 22C3’ by Agilent Technologies Inc. for use in urothelial carcinoma. The assay is the only approved ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for ...
Agilent Technologies, Inc. A continues to gain traction in the medical diagnosis market on the back of advanced techniques as well as robust clinical and diagnostic product portfolio. This is evident ...
Agilent Technologies, Inc. A continues to gain traction in the medical diagnosis market on the back of advanced techniques, and robust clinical and diagnostic product portfolio. Notably, Agilent has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results